Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05203315 · ClinicalTrials.gov registry record · Phase 3
Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults
A Phase 3 study, sponsored by Austin Institute for Clinical Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
NCT05203315: Completed Phase 3 study, sponsored by Austin Institute for Clinical Research.
NCT05203315 is a Phase 3 study that has completed, run by Austin Institute for Clinical Research. The registered enrollment target is 21 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05203315, a Phase 3 study, has completed, sponsored by Austin Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study seeks to evaluate the safety, tolerability, and efficacy of topical Duobrii® Lotion in adult subjects with mild plaque psoriasis.
Primary Outcome
The primary efficacy endpoint will be the percent of subjects with treatment success, defined as an Investigators Global Assessment (IGA) score equating to "Clear". 0: Clear, 1: Mild, 2: Moderate, 3: Severe.
Interventions
- DRUG Duobrii 0.01 % / 0.045 % Topical Lotion
- DRUG CeraVe, Topical Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2023-10-04 |
| Phase | Phase 3 |
What the finished NCT05203315 record still lists
NCT05203315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Duobrii 0.01 % / 0.045 % Topical Lotion is the first listed.
NCT05203315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05203315 about?
NCT05203315 is a clinical study titled "Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults". This study seeks to evaluate the safety, tolerability, and efficacy of topical Duobrii® Lotion in adult subjects with mild plaque psoriasis.
What is the current status of trial NCT05203315?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2022-01-13. Estimated completion is 2023-10-04.
What interventions are being tested in trial NCT05203315?
The interventions under investigation include: Duobrii 0.01 % / 0.045 % Topical Lotion (DRUG), CeraVe, Topical Cream (DRUG).
Who is sponsoring clinical trial NCT05203315?
This trial is sponsored by Austin Institute for Clinical Research, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05203315's enrollment target sits among peer trials
21 1953rd of 2000 higher than 45 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI